Washington, USA – Oral Presentation and Posters 30 August- 2 September, 2026 Isabel Leroux-Roels, Center for Vaccinology (CEVAC) – Ghent University Hospital to present Phase 2b field efficacy trial results as part of a presentation entitled “Phase 2b ASUNIVA topline results on efficacy safety and immunogenicity of OVX836 a broad-spectrum influenza A vaccine”. Alexandre …
Continuer la lecture « Options XIII for the Control of Influenza »
Brisbane, Australia – Oral Presentation and PostersAlexandre Le Vert, Chief Executive Officer & Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “OVX836, A NP-Based Universal Influenza Vaccine Candidate, Triggers Effector CD4+ and Cytotoxic CD8+ T-Cells in Healthy Adults”. Delphine Guyon-Gellin, Chief of Business Development & Chief Operating …
Continuer la lecture « Options XII for the Control of Influenza »
